INSILEX
Computational Precision Medicine for In-Silico Trials of Medical Devices
Funder: Royal Academy of Engineering Chair in Emerging Technologies
Period: 2019 – 2029
Principal Investigator: Prof. Alejandro F. Frangi
overview
INSILEX — Computational Precision Medicine for In-Silico Trials of Medical Devices envisions a paradigm shift in medical device innovation, where quantitative sciences are exploited to carefully engineer medical device designs, explicitly optimise clinical outcomes, and thoroughly test side-effects before being marketed.
Using a case study on flow-diversion devices and coils for the endovascular treatment of haemorrhagic stroke, INSILEX lays the computational foundations and evidence for accelerating the adoption of in-silico trials as an early and cost-effective source of scientific evidence.
expected outcomes
Within ten years, INSILEX will have transformed medical device design and evaluation, delivering these expected outcomes:
- Minimise animal/human suffering by reducing, refining, and replacing animal/human testing.
- Advance personalised treatment towards customised medical devices and precision medicine.
- Develop medical devices optimised for robustness to uncertainty and lifestyle profiles.
- Achieve a marked decrease in long-term device failures and an increase in beneficial patient outcomes.
- Improve cost-effectiveness by quicker execution at a fraction of the cost of a full-scale live trial.